The FDA approved a kinase inhibitor for the treatment of inflammatory myofibroblastic tumors in children and adults. The U.S. Food and Drug Administration has approved crizotinib (Xalkori) for the treatment of certain patients 1...
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for the second-line...
Ibrutinib, a small molecule inhibitor of B-cell proliferation, was approved for pediatric patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) for pediatric patients 1 year of...
The FDA approved a combination of two kinase inhibitors for the treatment of solid tumors bearing the BRAF V600E mutation. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the kinase...
The FDA has approved an immunotherapy to be used in combination with another immunotherapy or chemotherapy for the treatment of esophageal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved the...
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tisagenlecleucel (Kymriah) for certain adult patients...
The FDA approved a new regimen that includes a molecularly targeted therapeutic for some older leukemia patients not eligible for intensive chemotherapy. The U.S. Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) in...
The FDA approved the chemotherapeutic azacitidine for patients with juvenile myelomonocytic leukemia The U.S. Food and Drug Administration (FDA) has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Azacitidine...
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of certain adult...
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More